Novartis, CH0012005267

Novartis stock after-hours at EUR 125.66: minus 2.04 percent versus prior close

Published on 09/30/2026 at 22:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novartis stock was at EUR 125.66 after-hours at 10:29 p.m. CEST on September 30, 2026, down 2.04 percent versus the prior close at Lang & Schwarz. Earlier, the company reported regulatory and trial updates.

Pop-Art-Illustration einer DNA-Doppelhelix mit Kapsel in leuchtendem Halftone-Raster
Novartis AG CH0012005267 – Pop-Art-Comic mit stilisierter DNA-Helix und Kapsel im bunten Halftone-Raster, Illustration mit AI erstellt.

Novartis stock was at EUR 125.66 after-hours at 10:29 p.m. CEST on September 30, 2026, down EUR 2.62, or 2.04 percent, versus the EUR 128.28 prior close at Lang & Schwarz.

Trading day in Frankfurt

The latest price indication was recorded at Lang & Schwarz in euros. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Novartis stock.

Recent regulatory and pipeline updates

In a September 18, 2026 release, Novartis said the European Medicines Agency’s Committee for Medicinal Products for Human Use had adopted a positive opinion recommending marketing authorization for Cosentyx in adults with polymyalgia rheumatica who had an inadequate response to steroids or relapsed during steroid taper. The company said a European Commission decision was expected within approximately two months. Novartis

In a September 8, 2026 release, Novartis reported that the Phase III HARBOR study of del-desiran in myotonic dystrophy type 1 did not demonstrate statistically significant improvement versus placebo on its primary endpoint. The company said it was evaluating the full dataset and maintained its 5% to 6% five-year sales compound annual growth guidance for 2025 through 2030. Novartis

Disclaimer...

en | CH0012005267 | NOVARTIS | boerse | 70206583 | bgmi